Keytruda

DRUG18 trials

Conditions

Anti-PD1 AntibodyBile Duct CancerBiliary CancerBreast CancerCancer of the Bile DuctColorectal CancerGastric CancerHepatocellular Carcinoma

Phase 1

3rd Generation GD-2 Chimeric Antigen Receptor and ICaspase Suicide Safety Switch, Neuroblastoma, GRAIN

Active, not recruitingNCT01822652

Baylor College of MedicineNeuroblastoma

Start: 2013-08-31End: 2030-10-31Updated: 2025-02-24

Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

CompletedNCT02635672

Vincerx Pharma, Inc.Neoplasms

Start: 2016-02-10End: 2024-11-11Target: 110Updated: 2024-11-15

Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer

TerminatedNCT02842125

MultiVir, Inc.Metastatic Solid Tumor Cancer, Recurrent Head and Neck Cancer

Start: 2018-11-20End: 2020-05-08Updated: 2020-06-02

OH2 Injection in Solid Tumors

RecruitingNCT04386967

Binhui Biopharmaceutical Co., Ltd.Melanoma, Solid Tumor

Start: 2018-11-22End: 2026-12-13Target: 30Updated: 2025-07-25

Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies

NCT05739006

BiocadMelanoma, Non Small Cell Lung Cancer

Start: 2021-02-08End: 2023-08-31Updated: 2023-08-02

A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

RecruitingNCT05849480

National Cancer Institute (NCI)Bile Duct Cancer, Biliary Cancer, Cancer of the Bile Duct

Start: 2024-05-08End: 2042-06-01Target: 60Updated: 2026-03-24

Clinical Trial of TB511 in Advanced Solid Tumors

Not yet recruitingNCT06400160

Twinpig Biolab, Inc.Colorectal Cancer, Hepatocellular Carcinoma, NSCLC +1

Start: 2026-03-31End: 2028-03-31Target: 12Updated: 2025-11-25

Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients

Active, not recruitingNCT06551064

Formycon AGMelanoma, Stage II, Melanoma Stage III

Start: 2024-07-01End: 2026-06-30Updated: 2025-09-04

Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)

Not yet recruitingNCT07388550

National Institute of Neurological Disorders and Stroke (NINDS)Post-Acute COVID-19 Syndrome

Start: 2026-04-08End: 2028-01-01Target: 15Updated: 2026-04-03

A Randomized, Double-Blind, Pharmacokinetic Similarity Study to Compare AVT32-DRL_PB With Keytruda® in Participants With Fully Resected Melanoma

Not yet recruitingNCT07475572

Alvotech Swiss AGMelanoma

Start: 2026-06-19End: 2028-04-14Target: 120Updated: 2026-03-16

Phase 2

Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma

CompletedNCT04798781

Andrew Hendifar, MDGastric Cancer, Hepatocellular Carcinoma

Start: 2021-07-28End: 2025-10-20Updated: 2025-12-11

Preoperative Immunotherapy Combined With Stereotactic Radiation Therapy Boost in the Treatment of HER2-negative Breast Cancer

RecruitingNCT06472583

Maria Sklodowska-Curie National Research Institute of OncologyBreast Cancer

Start: 2024-04-11End: 2028-02-28Target: 78Updated: 2024-06-25

IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer

RecruitingNCT07122687

Innovent Biologics (Suzhou) Co. Ltd.Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer

Start: 2025-08-26End: 2030-04-30Target: 170Updated: 2025-09-30

Phase 3

Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced Melanoma

NCT05986331

BiocadMelanoma (Skin)

Start: 2022-07-18End: 2024-12-31Updated: 2023-09-21

A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer

Active, not recruitingNCT06348199

Samsung Bioepis Co., Ltd.Non-small Cell Lung Cancer Stage IV

Start: 2024-03-12End: 2026-09-30Updated: 2025-11-17

TerminatedNCT06643117

Formycon AGNon Small Cell Lung Cancer, Non-Squamous Non-Small Cell Lung Cancer

Start: 2024-10-03End: 2025-05-13Updated: 2025-06-26

Unknown Phase

Axitinib Therapy Management Study

WithdrawnNCT04555603

PfizerRenal Cell Carcinoma

Start: 2020-09-15End: 2021-02-22Updated: 2023-11-21

Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma

CompletedNCT04627012

Sun Yat-sen UniversityAnti-PD1 Antibody, Hepatocellular Carcinoma, Liver Diseases

Start: 2018-01-01End: 2023-07-01Updated: 2024-03-06

Journal for ImmunoTherapy of Cancer2025-02-0115 citations

Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers

Journal for ImmunoTherapy of Cancer2024-05-0143 citations

Abstract C076: Evidence of TCR and BCR clonal dynamics with enitociclib monotherapy in patients with MYC+ non-Hodgkin lymphoma (NHL)

Molecular Cancer Therapeutics2023-12-01

Abstract 1859: VIP152, a selective CDK9 inhibitor, demonstrates sensitivity in gynecologic cell lines that are cisplatin sensitive or resistant and delivers <i>in vivo</i> antitumor efficacy

Cancer Research2022-06-152 citations

A phase Ia/Ib study evaluating the safety and efficacy of intratumorally administrated OH2, an oncolytic herpes simplex virus 2, in unresected stage IIIC to IV melanoma patients.

Journal of Clinical Oncology2022-06-013 citations

P1269: VIP152 IS A NOVEL CDK9 INHIBITOR WITH IMPROVED SELECTIVITY, TARGET MODULATION, AND CARDIAC SAFETY IN PATIENTS WITH LYMPHOMA

HemaSphere2022-06-012 citations

First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy

Clinical Cancer Research2022-01-1851 citations

VIP152, a Selective CDK9 Inhibitor, Induces Complete Regression in a High-Grade B-Cell Lymphoma (HGBL) Model and Depletion of Short-Lived Oncogenic Driver Transcripts, MYC and MCL1, with a Once Weekly Schedule

Blood2021-11-052 citations

Safety and efficacy of VIP152, a CDK9 inhibitor, in patients with double-hit lymphoma (DHL).

Journal of Clinical Oncology2021-05-2021 citations

Phase I dose escalation study of the first-in-class selective PTEFb inhibitor BAY 1251152 in patients with advanced cancer: Novel target validation and early evidence of clinical activity.

Journal of Clinical Oncology2018-05-2013 citations

Abstract 984: Identification of potent and highly selective PTEFb inhibitor BAY 1251152 for the treatment of cancer: from p.o. to i.v. application via scaffold hops

Cancer Research2017-07-0128 citations

Effect of adenoviral p53 (Ad-p53) tumor suppressor immune gene therapy on checkpoint inhibitor resistance and abscopal therapeutic efficacy.

Journal of Clinical Oncology2017-05-205 citations